Status:
COMPLETED
Evaluating Multiple Sclerosis Patients ShOWing A GEnomic Signature of Therapy Response
Lead Sponsor:
DxTerity Diagnostics
Conditions:
Multiple Sclerosis
MS
Eligibility:
All Genders
18+ years
Brief Summary
To develop a test to characterize and monitor Multiple Sclerosis (MS) disease status and therapy response from a participant's home by analyzing the gene expression from participant self-collected blo...
Detailed Description
Multiple Sclerosis (MS) is an autoimmune disease that damages the central nervous system (CNS) and disrupts communication to and from the brain by attacking the myelin sheath surrounding neurons. It i...
Eligibility Criteria
Inclusion
- Male and female patients age 18 or older
- Have a permanent address in the United States for the duration of the study
- Have an email address and access to the internet for the duration of the study
- Able to provide informed consent
- Self-reported diagnosis of MS
Exclusion
- None
Key Trial Info
Start Date :
November 7 2017
Trial Type :
OBSERVATIONAL
Allocation :
ACTUAL
End Date :
February 25 2020
Estimated Enrollment :
1168 Patients enrolled
Trial Details
Trial ID
NCT03316404
Start Date
November 7 2017
End Date
February 25 2020
Last Update
August 6 2024
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
DxTerity Diagnostics
Compton, California, United States, 90220